Zipalertinib Plus Chemotherapy Meets Primary Pfs Endpoint In Planned Interim Analysis Of Phase 3 Rezilient3 Trial
13/08/2026 24:32
BRIEF-Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Meets Primary Pfs Endpoint In Planned Interim Analysis Of Phase 3 Rezilient3 Trial Aug 13 (Reuters) - Otsuka Holdings Co., Ltd. 4578.T:
OTSUKA HOLDINGS CO., LTD.: ZIPALERTINIB PLUS CHEMOTHERAPY MEETS PRIMARY PFS ENDPOINT IN PLANNED INTERIM ANALYSIS OF PHASE 3 REZILIENT3 TRIAL
Source text: ID:nTStl7ea4e
Further company coverage: 4578.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug